Biognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference
“While this is one of the feature richest releases we ever had, it’s the improvement in quantification that stands out in Spectronaut 19,” said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys.
- “While this is one of the feature richest releases we ever had, it’s the improvement in quantification that stands out in Spectronaut 19,” said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys.
- The method offers excellent quantitation and higher throughput for large-cohort biomarker or drug discovery studies, and clinical, epidemiological, or population proteomics research.
- Biognosys’ new data insights solution, DigitalProteome™, provides valuable insights into protein expression and significantly enhances in-vivo biomarker discovery and drug development studies.
- Visit https://biognosys.com/asms2024 for a complete overview of Biognosys’ presence at ASMS.